ライフサイエンスコーパス: randomly assign @1 patients to

1 In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg dai

2 We randomly assigned 2000 patients to BIS-guided anesthesia

3 Using a 2-by-2 factorial design, we randomly assigned 452 patients to chemotherapy with or w

4 Between Dec 22, 2008, and May 26, 2011, we randomly assigned 221 patients to chlorambucil plus ofat

5 We randomly assigned 22 patients to conventional haemorrhoi

6 Between Dec 23, 2009, and June 11, 2013, we randomly assigned 480 patients to dacomitinib and 240 pa

7 Between Oct 29, 2010, and Oct 4, 2012, we randomly assigned 225 patients to dapagliflozin and 224

8 etes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to a

9 7, 2013, and March 25, 2014, we enrolled and randomly assigned 365 patients to different treatment ar

10 Between Jan 7, 2004, and May 24, 2012, we randomly assigned 425 patients to each treatment group.

11 We randomly assigned 920 patients to either "invasive" mana

12 We randomly assigned eligible patients to either intraarter

13 4, 2010, and Dec 21, 2010, we recruited and randomly assigned 73 patients to elotuzumab (36 to 10 mg

14 b 7, 2013, and July 1, 2014, we enrolled and randomly assigned 42 patients to erlotinib treatment, 40

15 Between Feb 4, 2015, and July 12, 2016, we randomly assigned 294 patients to extrafine inhaled cort

16 Between Jan 1, 2014, and April 11, 2015, we randomly assigned 50 patients to group 1 (n=25) or group

17 We randomly assigned 807 patients to groups that received o

18 We randomly assigned 1623 patients to lenalidomide and dexa

19 We randomly assigned 251 patients to mitral-valve repair or

20 From April 13, 2011, to Sept 21, 2012, we randomly assigned 276 patients to montelukast (n=137) or

21 Between June 25, 2014, and June 15, 2015, we randomly assigned 444 patients to neoadjuvant treatment

22 , we screened 179 patients and enrolled 142, randomly assigning 95 patients to nivolumab plus ipilimu

23 etween June 13, 2008, and April 26, 2012, we randomly assigned 355 patients to ombrabulin plus cispla

24 tional Single Ventricle Reconstruction trial randomly assigned 555 patients to one or the other shunt

25 We randomly assigned 96 patients to one of the four study g

26 We randomly assigned the patients to one of four treatment

27 In a double-blind fashion, we randomly assigned 1133 patients to placebo and 1156 pati

28 We randomly assigned 22 patients to placebo or IL-1ra (1:1)

29 ath in Heart Failure Trial (SCD-HeFT), which randomly assigned 2521 patients to placebo, amiodarone,

30 We randomly assigned the patients to placebo, losartan (100

31 ratified randomization algorithm was used to randomly assign eligible patients to receive usual care,

32 We randomly assigned 101 patients to receive placebo (n=50)

33 We randomly assigned 1015 patients to receive doses of warf

34 In this double-blind study, we randomly assigned 1088 patients to receive abiraterone a

35 Between Feb 22, 2013, and May 13, 2015, we randomly assigned 120 patients to receive methotrexate (

36 We randomly assigned 1206 patients to receive neoadjuvant t

37 Between Dec 3, 2007, and March 8, 2010, we randomly assigned 1290 patients to receive chemotherapy

38 We randomly assigned 135 patients to receive a central veno

39 tween March 23, 2012, and March 31, 2014, we randomly assigned 136 patients to receive brief guided p

40 We randomly assigned 138 patients to receive G-CSF (n=71) o

41 Between June 12, 2012, and June 24, 2013, we randomly assigned 140 patients to receive placebo (n=62)

42 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination th

43 In this double-blind, phase 3 study, we randomly assigned 1717 patients to receive either enzalu

44 Between Aug 20, 2012, and June 17, 2013, we randomly assigned 176 patients to receive subcutaneous r

45 etween June 14, 2010, and April 21, 2011, we randomly assigned 192 patients to receive axitinib, and

46 le for high-dose interferon alfa therapy, we randomly assigned 20 patients to receive the antidepress

47 Between July 1, 2011, and Nov 4, 2015, we randomly assigned 200 patients to receive standard treat

48 We randomly assigned 2013 patients to receive bare-metal, z

49 We randomly assigned 2254 patients to receive liraglutide (

50 Between Aug 10, 2010, and May 14, 2015, we randomly assigned 229 patients to receive placebo (n=114

51 Between March 26, 2013, and Aug 26, 2014, we randomly assigned 230 patients to receive ataluren (n=11

52 We randomly assigned 234 patients to receive standard chemo

53 ounger than 66 years of age at diagnosis, we randomly assigned 240 patients to receive rituximab main

54 In two separate trials, we randomly assigned 245 patients to receive in-center dail

55 Between July 9, 2012, and Feb 5, 2014, we randomly assigned 250 patients to receive either AAV1/SE

56 Between Oct 16, 2012, and Dec 13, 2014, we randomly assigned 252 patients to receive either artesun

57 cancer that was refractory to iodine-131, we randomly assigned 261 patients to receive lenvatinib (at

58 Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n

59 We randomly assigned 272 patients to receive nivolumab, at

60 We randomly assigned 29 patients to receive either metformi

61 Between Oct 29, 2014, and Aug 19, 2016, we randomly assigned 298 patients to receive at least one d

62 We randomly assigned 300 patients to receive 900 mug of sub

63 We randomly assigned 302 patients to receive induction chem

64 We randomly assigned 323 patients to receive three subcutan

65 In this open-label phase 3 study, we randomly assigned 3360 patients to receive standard adju

66 etween April 14, 2005, and April 1, 2009, we randomly assigned 350 patients to receive erlotinib and

67 We randomly assigned 40 patients to receive either an intra

68 We randomly assigned 42 patients to receive oral doses of s

69 etween April 20, 2009, and June 30, 2010, we randomly assigned 44 patients to receive selumetinib and

70 Between Oct 4, 2011, and Feb 22, 2014, we randomly assigned 452 patients to receive placebo (n=151

71 Between June 29, 2010, and Jan 17, 2013, we randomly assigned 470 patients to receive the brief psyc

72 Between Dec 6, 2005, and Dec 21, 2012, we randomly assigned 477 patients to receive either radioth

73 pairment 6 months or more after a stroke, we randomly assigned 49 patients to receive intensive robot

74 2013, and Nov 7, 2013, and Aug 26, 2014, we randomly assigned 50 patients to receive CBT plus standa

75 We randomly assigned 553 patients to receive imatinib and 5

76 In two consecutive overnight sessions, we randomly assigned 56 patients to receive treatment with

77 We randomly assigned 599 patients to receive once-weekly du

78 Between April 27, 2009, and Oct 31, 2009, we randomly assigned 60 patients to receive either medical

79 We randomly assigned 60 patients to receive vancomycin (n =

80 Between Nov 11, 2009, and Feb 2, 2011, we randomly assigned 633 patients to receive either necitum

81 Between Sept 4, 2014, and Oct 15, 2015, we randomly assigned 695 patients to receive exenatide plus

82 In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9

83 We randomly assigned 77 patients to receive a continuous in

84 Between Jan 3, 2013, and Sept 24, 2014, we randomly assigned 860 patients to receive solithromycin

85 Between Dec 9, 2010, and Sept 21, 2012, we randomly assigned 884 patients to receive dulaglutide 1.

86 Between May 14, 2009, and May 9, 2013, we randomly assigned 98 patients to receive either eltrombo

87 We randomly assigned the patients to receive either ribocic

88 We randomly assigned the patients to receive peginterferon

89 We randomly assigned these patients to receive a total of 4

90 Three hundred twenty-six patients were randomly assigned; 163 patients to SC and 163 to LC.

91 ll patients received sevelamer carbonate, we randomly assigned 109 patients to sevelamer (n=55) or pl

92 tween April 12, 2011, and March 30, 2012, we randomly assigned 758 patients to smear microscopy (182

93 dian age 2.95 years (range 1.03-20.97), were randomly assigned-132 patients to standard and 130 patie

94 We randomly assigned 351 patients to surgery and postoperat

95 Between Dec 16, 1992, and May 22, 2001, we randomly assigned 900 patients to surgery with either a

96 Between June 29, 2010, and Sept 16, 2013, we randomly assigned 130 patients to the Organ Care System

97 Between Aug 13, 2009, and May 30, 2014, we randomly assigned 1313 patients to the control group (n=

98 We randomly assigned 162 patients to the salbutamol group a

99 Between Aug 24, 2010, and Nov 13, 2012, we randomly assigned 2103 patients to the tiotropium 5 mug

100 Between Feb 23, 2011, and March 29, 2013, we randomly assigned 252 patients to the pitavastatin (n=12

101 Between April 6, 2010, and Sept 21, 2012, we randomly assigned 329 patients to the brentuximab vedoti

102 In cohort 1, we randomly assigned 60 patients to the 12-week regimen (31

103 n and 31 with no ribavirin); in cohort 2, we randomly assigned 65 patients to the 12-week regimen (32

104 GS: Between Feb 3, 2011, and Dec 1, 2011, we randomly assigned 88 patients to the Trevo Retriever gro

105 The Bayesian adaptive trial randomly assigned more patients to the better-performing

106 Between Nov 19, 2010, and Dec 12, 2014, we randomly assigned 1794 patients to treatment, of whom 17

107 Between Sept 14, 2012, and June 16, 2015, we randomly assigned 313 patients to treatment groups (106

108 From March 17, 2010, to Jan 15, 2013, we randomly assigned 67 patients to treatment, with 45 pati

109 Between Sept 1, 2010, and April 22, 2013, we randomly assigned 7028 patients to treatment groups and

110 a double-blind, placebo-controlled study, we randomly assigned 77 patients to treatment with celecoxi

111 Between July 25, 2012, and Jan 12, 2016, we randomly assigned 878 patients to treatment: 294 to plac

112 We randomly assigned 301 patients to undergo either CABG al

113 We randomly assigned 50 patients to undergo on-pump coronar

114 ospective, controlled, multicenter trial, we randomly assigned 91 patients to undergo transmyocardial

115 We randomly assigned 75 patients to usual care and 227 pati

116 etween March 8, 2011, and April 30, 2013, we randomly assigned 206 patients to vascular-targeted phot